All News
Filter News
Found 9,342 articles
-
Former Head of Boehringer Ingelheim Animal Health, Dr. Joachim Hasenmaier, Joins Invetx Board of Directors
1/6/2021
Invetx, a pioneer in protein-based therapeutics for animal health, announced that Dr. Joachim Hasenmaier has joined the company’s board of directors.
-
Seelos Therapeutics Announces Year End 2020 Business Update
1/6/2021
-Highlights of Continued Execution of Plans for Multiple Clinical Programs and Upcoming Catalysts -Additions to the Clinical, Operational and Regulatory Teams
-
Verastem Oncology Appoints Frank Neumann, M.D., Ph.D., as Chief Medical Officer
1/6/2021
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the appointment of industry veteran Frank Neumann, M.D., Ph.D., as Chief Medical Officer
-
Chronic Kidney Disease (CKD) Drugs Market: Increasing Burden of Kidney Disease is Expected to Drive the Market
1/6/2021
The demand graph of the global chronic kidney disease drugs market is treading along a lucrative track. The importance of healthy kidneys for the human body cannot be underestimated.
-
Pharvaris Expands Board of Directors with Appointment of David Meeker, M.D., as Chair and Robert Glassman, M.D., as Director
1/5/2021
Pharvaris, a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced two key appointments to its Board of Directors: David Meeker, M.D., as Chair and Robert Glassman,
-
Innate’s First NK Cell Engager Selected by Sanofi as Drug Candidate for Development
1/5/2021
IPH6101/SAR443579 is an NKp46-based NK cell engager (NKCE) that uses Innate’s proprietary multispecific antibody format
-
DURECT Corporation Appoints Two New Board Members
1/5/2021
DURECT Corporation announced the appointment of two new members to its board of directors, Gail J. Maderis, MBA and Mohammad Azab, M.D., M. Sc., MBA, two senior industry veterans with extensive drug development, clinical research and medical affairs experience.
-
Global self-monitoring blood glucose market size to expand at 4.2% CAGR through 2027
1/5/2021
The business intelligence report on ‘Global Self-Monitoring Blood Glucose Market’ is consists of business analysis over the historical period of 2017-2019, while studying the prevailing trends and the latest developments to reckon market valuation by the year 2027.
-
Global Biotechnology Market: 4 pivotal trends expected to augment the industry size through 2025
1/5/2021
One of the recent developments in the biotechnology market comprises the development of a promising solution to the problem of unwanted genetic changes associated with CRISPR-Cas9.
-
Cutaneous Squamous Cell Carcinoma Treatment Market is likely to show upward revenues curve by 2029
1/5/2021
The global cutaneous squamous cell carcinoma treatment market is likely to show upward revenues curve during the forecast period of 2019 to 2029.
-
As the sun rose on a new year, approximately 70 companies raised the price of hundreds of prescription drugs by an average of 3.3%.
-
Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer
1/4/2021
Cassava Sciences, Inc. (Nasdaq: SAVA) a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the appointment of James Kupiec, MD, to the newly created position of Chief Clinical Development Officer. Dr. Kupiec will lead the Phase 3 clinical development strategy for simufilam, Cassava Sciences’ investigational drug for the treatment of dementia in Alzheimer’s disease. Dr. Kupiec will also serve as a member of the e
-
Innate Pharma to Participate in Upcoming Investor Conferences - Jan 04, 2021
1/4/2021
Innate Pharma SA announced that members of its senior management team are scheduled to participate in the following upcoming virtual investor conferences.
-
Specialty Active Pharmaceutical Ingredients Market: Notable Developments & Geographical Outlook
1/3/2021
The global specialty active pharmaceutical ingredients market is expected to witness a promising growth opportunities in the coming years of the forecast period.
-
Knee Hyaluronic Acid Injections Market: Research and development activities play a crucial role in the growth of the market
1/3/2021
The knee hyaluronic acid injections market is expected to observe considerable growth across the forecast period of 2020-2030.
-
Fabry disease is a rare, X-linked inherited disease that results from abnormal deposits of a fatty substance in blood vessels.
-
AHF Thanks HHS for Clarifying Rules on 340B Drug Pricing; Blasts Pharma’s Greed
12/30/2020
AIDS Healthcare Foundation welcomed and praised an advisory opinion issued earlier by the Office of the General Counsel for the United States Health and Human Services Department which concluded that drug manufacturers are required to deliver discounts under the 340B Drug Pricing Program on covered outpatient drugs when contract pharmacies are acting as agents of 340B covered entities.
-
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease
12/30/2020
A decline trend in patients' renal function on agalsidase alfa was attenuated and improved to be similar to normal renal function decline when switched to PRX-102
-
Regeneron Announces Encouraging Initial Data from COVID-19 Antibody Cocktail Trial in Hospitalized Patients on Low-flow Oxygen
12/29/2020
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced encouraging initial data from an ongoing Phase 1/2/3 clinical trial of the Regeneron antibody cocktail, casirivimab and imdevimab, in hospitalized COVID-19 patients requiring low-flow oxygen.
-
Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®
12/29/2020
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they will supply an additional 100 million doses of COMIRNATY®, the companies’ COVID-19 Vaccine, to the 27 European Union (EU) member states in 2021.